Latest Research And Development News

Chrysos Corporation reports nearly one million monthly PhotonAssay samples and reiterates strong FY26 revenue guidance, while unveiling next-gen assay technologies and global expansion plans.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Wide Open Agriculture has received a $586,624 tax rebate for its overseas research activities in Germany, supporting the commercialisation of its proprietary lupin protein products.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.

DroneShield Limited reaffirms strong business fundamentals with record revenues in 2025, while addressing recent media reports and initiating an independent governance review.

Gentrack Group reported robust FY25 results with an 8% revenue rise to NZ$230.2m and a 119% jump in net profit, driven by strong growth in utilities and airports segments alongside strategic investments in its new cloud platform and global expansion.

Gentrack Group reported a strong FY25 with revenue up 8% and net profit more than doubling, driven by key deployments of its new g2.0 cloud platform and robust growth in its airports division Veovo.

Janus Electric Holdings has updated its FY25 financials with audited figures, correcting prior R&D expense misstatements and recognizing an impairment on its Vaulta investment, resulting in a net loss of $8.9 million.

ReNerve Limited has raised $3.2 million through a two-tranche share placement to accelerate its sales and marketing efforts in the US and support upcoming product launches, including a new nerve conduit range.

LaserBond’s 2025 AGM reveals a pivotal CEO transition alongside a strong financial rebound driven by strategic investments and technology licensing deals.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.